Patent 11767359 was granted and assigned to NGM Biopharmaceuticals on September, 2023 by the United States Patent and Trademark Office.
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.